Company / SG&A Expense
Senti Biosciences Holdings, Inc. SG&A Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$26.4M
FY2025
5-year range
$21.3M / $38.2M
FY2022-FY2025
Trend
-29.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $38M to $26M over the past 2 years.
Based on SEC 10-K filings.
$26M in FY2025 with a 3-year CAGR of +7.5%.
Improved from $38M to $26M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +7.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +7.5%, indicating consistent growth.
- In FY2025, sg&a expense decreased 29.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.4M | -29.1% |
| FY2024 | $37.2M | -2.7% |
| FY2023 | $38.2M | +79.9% |
| FY2022 | $21.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026